• D Micić, M Sumarac-Dumanović, V Popović, D Manojlović, and F Kazanueva.
• Srp Ark Celok Lek. 1995 Jan 1; 123 (1-2): 141-4.

AbstractGrowth hormone (GH) response to dexamethasone (DEX) in 10 poorly controlled insulin dependent diabetic patients (IDDM) without clinical evidence of diabetic complications and in 10 healthy controls, was studied. GH responses to DEX were compared with pituitary GH response to growth hormone releasing hormone (GHRH). Fasting GH values were not significantly higher in IDDM in comparison with the controls. The peak GH responses to GHRH and DEX were similar in the controls and IDDM patients (23.8 +/- 6.49 vs 38.87 +/- 7.26, p > 0.05 in GHRH test and 13.71 +/- 3.59 vs 17.33 +/- 5 23, p > 0.05 in DEX test). No significant difference between area under curve during GHRH (1386. +/- 490.69 vs 1966.89 +/- 561.46, p > 0.05) and during DEX test (1085.8 +/- 239 856 vs 501.87 +/- 847.16, p > 0 05) in the controls and IDDM patients, were established There was no significant correlation between basal and peak GH values and AUC during both tests, and HbA1C and duration of diabetes It is concluded that GH response to GHRH was normal and that our patients had preserved the integrity of the hypothalamo-pituitary axis, thanks to the suggested mechanism of dexamethasone action via somatostatin.

15 keywords...

hide…